Changes in vitamin D metabolites during teriparatide treatment

Bone

Volumn 50, Issue 6, 2012, Pages 1368-1371

  Cosman, Felicia ^a,b   Dawson Hughes, Bess ^c   Wan, Xiaohai ^d   Krege, John H ^d  

^a HELEN HAYES HOSPITAL   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c TUFTS UNIVERSITY   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

1,25 dihydroxyvitamin D; 25 hydroxyvitamin D; Osteoporosis; Teriparatide; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

25 HYDROXYCOLECALCIFEROL BLOOD LEVEL; ADULT; AGED; ARTICLE; CALCITRIOL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; TERIPARATIDE; VITAMIN D;

EID: 84860809452     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.02.635     Document Type: Article

References (21)

1. Garabedian M., Holick M.F., Deluca H.F., Boyle I.T. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci U S A 1972, 69:1673-1676.
2. Deluca H.F. Parathyroid hormone as a trophic hormone for 1,25-dihydroxyvitamin D3, the metabolically active form of vitamin D. NEJM 1972, 287:250-251.
3. Parfitt A.M., Gallagher J.C., Heaney R.P., Johnston C.C., Neer R., Whedon G.D. Vitamin D and bone health in the elderly. Am J Clin Nutr 1982, 36:1014-1031.
4. Slovik D.M., Adams J.S., Neer R.M., Holick M.F., Potts J.T. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 1981, 305:372-374.
5. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
6. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
7. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
8. Tsujimoto M., Chen P., Miyauchi A., Sowa H., Krege J.H. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011, 48:798-803.
9. Graeff C., Chevalier Y., Charlebois M., Varga P., Pahr D., Nickelsen T.N., et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 2009, 24:1672-1680.
10. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22:149-157.
11. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
12. Prevrhal S., Krege J.H., Chen P., Genant H., Black D.M. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 2009, 25:921-928.
13. Licata A.A. Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med 2005, 352:1930-1931.
14. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
15. Bouillon R.A., Auwerx J.H., Lissens W.D., Pelemans W.K. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr 1987, 45:755-763.
16. Holick M.F. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990, 120:1464-1469.
17. Slovik D.M., Rosenthal D.I., Doppelt S.H., Potts J.T., Daly M.A., Campbell J.A., et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986, 1:377-381.
18. Manolagas S.C., Burton D.W., Deftos L.J. 1,25-Dihydroxyvitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem 1981, 256:7115-7117.
19. Cosman F., Nieves J., Shen V., Lindsay R. Oral 1,25-dihydroxyvitamin D administration in oststeoporotic women: effects of estrogen therapy. J Bone Miner Res 1995, 10:594-600.
20. Cosman F., Shen V., Morgan D., Gordon S., Parisien M., Nieves J., et al. Biochemical responses of bone metabolism to 1,25-dihydroxyvitamin D administration in black and white women. Osteoporos Int 2000, 11:271-277.
21. Dawson-Hughes B., Chen P., Krege J.H. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007, 92:4630-4636.